405 related articles for article (PubMed ID: 33383060)
1. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M;
Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060
[TBL] [Abstract][Full Text] [Related]
2. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 inhibitors: clinical evidence and implementation.
Sabatine MS
Nat Rev Cardiol; 2019 Mar; 16(3):155-165. PubMed ID: 30420622
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
Board C; Kelly MS; Shapiro MD; Dixon DL
J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
[TBL] [Abstract][Full Text] [Related]
7. LDL cholesterol: How low to go?
Packard CJ
Trends Cardiovasc Med; 2018 Jul; 28(5):348-354. PubMed ID: 29336946
[TBL] [Abstract][Full Text] [Related]
8. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
9. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
Duprez DA; Handelsman Y; Koren M
Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
[TBL] [Abstract][Full Text] [Related]
11. Lipid management in ACS: Should we go lower faster?
Gencer B; Mach F
Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
14. Identifying Patients for Nonstatin Therapy.
Robinson JG; Watson KE
Rev Cardiovasc Med; 2018; 19(S1):S1-S8. PubMed ID: 30207552
[TBL] [Abstract][Full Text] [Related]
15. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.
Drexel H; Coats AJS; Spoletini I; Bilato C; Mollace V; Perrone Filardi P; Rosano GMC
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):115-121. PubMed ID: 31873726
[TBL] [Abstract][Full Text] [Related]
16. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
17. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
18. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
[TBL] [Abstract][Full Text] [Related]
19. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
Bittner V
Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
[No Abstract] [Full Text] [Related]
[Next] [New Search]
